Alexion buying Portola for $18/share
May 05, 2020 7:15 AM ETAlexion Pharmaceuticals, Inc. (ALXN), PTLAALXN, PTLABy: Stephen Alpher, SA News Editor41 Comments
- "Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care," says Alexion (NASDAQ:ALXN) CEO Ludwig Hantson.
- The $18 per share all-cash deal is more than double Portola's (NASDAQ:PTLA) close last night of $7.76. It's set to close in Q3.
- A conference call to discuss is set for 8 ET.